机译:比较Bevacizumab对糖尿病水肿患者Ranibizumab的疗效:BRDME研究
Univ Amsterdam Dept Ophthalmol Amsterdam UMC Amsterdam Netherlands;
Univ Amsterdam Dept Ophthalmol Amsterdam UMC Amsterdam Netherlands;
Univ Amsterdam Dept Ophthalmol Amsterdam UMC Amsterdam Netherlands;
Leiden Univ Dept Ophthalmol Med Ctr Leiden Netherlands;
Univ Groningen Univ Med Ctr Groningen Dept Ophthalmol Groningen Netherlands;
Univ Groningen Univ Med Ctr Groningen Dept Ophthalmol Groningen Netherlands;
Univ Amsterdam Amsterdam UMC Dept Clin Epidemiol Biostat &
Bioinformat Amsterdam Netherlands;
Queens Univ Belfast Dept Ophthalmol Belfast Antrim North Ireland;
Radboud Univ Nijmegen Dept Ophthalmol Med Ctr Nijmegen Netherlands;
Univ Med Ctr Utrecht Dept Ophthalmol Utrecht Netherlands;
Erasmus Univ Dept Ophthalmol Med Ctr Rotterdam Netherlands;
Vrije Univ Amsterdam Dept Ophthalmol Amsterdam UMC Amsterdam Netherlands;
Elisabeth Twee Steden ETZ Hosp Dept Ophthalmol Tilburg Netherlands;
Univ Amsterdam Amsterdam UMC Dept Clin Epidemiol Biostat &
Bioinformat Amsterdam Netherlands;
Vrije Univ Amsterdam Dept Ophthalmol Amsterdam UMC Amsterdam Netherlands;
机译:比较Bevacizumab对糖尿病水肿患者Ranibizumab的疗效:BRDME研究
机译:Bevacizumab与Ranibizumab在糖尿病黄斑水肿患者中的成本用途:BRDME研究分析
机译:比较贝伐单抗和雷珠单抗在糖尿病性黄斑水肿患者中的有效性和费用:一项随机临床试验(BRDME研究)
机译:贝伐单抗和兰尼单抗联合抗炎药的体外稳定性研究
机译:潮湿年龄相关性黄斑变性患者的ranibizumab治疗的表征反应模式:潜在的增长分析
机译:比较贝伐单抗和雷珠单抗在糖尿病性黄斑水肿患者中的有效性和费用:一项随机临床试验(BRDME研究)
机译:比较贝伐单抗和雷珠单抗在糖尿病性黄斑水肿患者中的有效性和费用:一项随机临床试验(BRDME研究)